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Abstract 
Background: Neuroimmune mechanisms have been linked to the pathophysiology of 
bipolar disorder based on studies of biomarkers in plasma, cerebrospinal fluid (CSF), 
and postmortem brain tissue. There are, however, no longitudinal studies investigating 
if CSF neuroimmune markers predict clinical outcomes and relate to markers of 
neuronal injury in patients with bipolar disorder. Here, we test the hypothesis that 
CSF markers of neuroimmune mechanisms are associated with neurochemical signs 
of neuronal injury and worse clinical outcome during long-term follow-up of patients 
with bipolar disorder. 
Methods: CSF concentrations of IL-8, MCP-1, YKL-40, and NF-L from 77 euthymic 
patients with bipolar disorder were analyzed at baseline. Associations to clinical 
outcomes assessed 6-7 years after baseline were investigated, and adjusted for 
confounding factors.  
Results: MCP-1 concentrations at baseline were positively associated with 
manic/hypomanic episodes and inpatient care during follow-up. YKL-40 
concentrations were negatively associated with manic/hypomanic episodes and with 
occurrence of psychotic symptoms. Only the negative association between YKL-40 
and manic/hypomanic episodes survived multiple testing correction.  
Conclusions: High concentrations of CSF markers of neuroimmune mechanisms were 
not related to biomarker signs of neuronal injury at baseline and not consistently 
associated with poor clinical outcomes as assessed after 6-7 years in this prospective 
study. These findings speak against a causal link between these proteins and disease 
progression. However, longitudinal studies of more neuroimmune markers across 




Bipolar disorder is a severe psychiatric condition characterized by recurrent episodes 
of elevated (mania or hypomania), depressed, or mixed mood (Belmaker 2004). 
Several lines of evidence indicate that the neuroimmune system and 
neuroinflammation play a role in the pathophysiology of bipolar disorder (Rosenblat 
et al. 2014). Neuroinflammation is a wide concept involving central nervous system 
(CNS) innate immunological responses (O'Callaghan et al. 2008). Microglia are the 
key cellular mediators of the intrinsic brain immune system and microglia activation 
is a central component of neuroinflammation. Microglia activation has been suggested 
to affect neuronal growth, differentiation, and function, and abnormal interactions 
between microglia and neurons might lead to a variety of psychiatric symptoms 
(Beumer et al. 2012). Activated microglia produce cytokines and chemokines, 
compounds that have been shown to impact synaptic plasticity, neurotransmitter 
metabolism, and neurocircuits relevant to mood regulation (McAfoose and Baune 
2009; Beumer et al. 2012; Haroon et al. 2012). Chronic exposure to elevated 
cytokines is further hypothesized to contribute to the development of mental disorders 
(Kraneveld et al. 2014).  
 
Although many studies show peripheral inflammation in psychiatric disorders, this is 
not synonymous with neuroinflammation or microglial activation in the CNS 
(Bhattacharya et al. 2016). Due to the relative impermeability of the blood–CSF 
(cerebrospinal fluid) barrier, concentrations of cytokines and other proteins in serum 
or plasma differ from the concentrations in CSF (Maier et al. 2005; Bromander et al. 
2012; Isgren et al. 2015). This means that altered concentrations of CSF proteins 
might be more sensitive and specific to CNS processes than equivalent blood 
alterations. Studies investigating neuroinflammation markers in CSF from patients 
with bipolar disorder are, however, scarce. In two previous studies, we found higher 
concentrations of interleukin-1β (IL-1 β) and interleukin-8 (IL-8) in euthymic patients 
with bipolar disorder compared with controls (Söderlund et al. 2011; Isgren et al. 
2015). For IL-8, there was a strong association to lithium- and antipsychotic 
treatment. In another study, we found higher concentration of two CSF markers of 
monocyte and microglia activation in bipolar disorder patients compared with 
controls: monocyte chemoattractant protein 1 (MCP-1; also called CCL-2) and 
chitinase-3-like protein 1 (CHI3L1; also called YKL-40) (Jakobsson et al. 2015). We 
further investigated CSF markers reflecting damages in brain cells and subcellular 
structures. Here, we found higher levels of neurofilament light chain (NF-L), a marker 
of axonal damage, in patients compared with controls, with a positive association to 
treatment with atypical antipsychotics (Jakobsson et al. 2014).  
 
Interestingly, cross-sectional studies have found associations between markers of 
neuroinflammation or neuronal injury on the one hand, and brain imaging findings, 
clinical features, cognition, and suicidality on the other. Thus, one recent study found 
that the inflammation-related cytokines TNF-α, IL-8, IFN-γ, and IL-10 measured in 
serum were associated with changes related to structural connectivity in cortico-
limbic networks in bipolar disorder (Benedetti et al. 2016). Another study found a 
possible relationship between manic symptomatology and pro-inflammatory gene 
expression in bipolar disorder (Haarman et al. 2014). We recently reported that 
cognitive impairment (executive function) in bipolar disorder was associated with 
higher levels of neuroinflammatory markers in CSF (Rolstad et al. 2015). In the same 
vein, CSF markers of neurodegeneration were associated with cognitive performance 
in patients with bipolar disorder, including a negative association between high NF-L 
concentrations and decreased performance in tests of verbal function and memory 
(Rolstad et al. 2015). Finally, lower plasma and CSF levels of IL-8 (Janelidze et al. 
2015), as well as lower CSF levels of MCP-1 (Janelidze et al. 2013), have been found 
in suicide attempters compared with healthy controls. 
 
Studies assessing prospective associations between neuroinflammation and clinical 
outcomes are, however, lacking (Barbosa et al. 2014). The question remains open 
whether neuroinflammation is associated with disease progression. Further, 
nonclassical immune actions of immune mediators and cells in the CNS have been 
shown in the absence of CNS pathology, stressing that homeostatic and adaptive 
immune processes can be mistaken for pathological processes (Estes and McAllister 
2014). Hence, although neuroinflammation might constitute a pathological 
mechanism in a causal model, it could also represent a reparative response to 
pathological mechanisms (Stertz et al. 2013; Barbosa et al. 2014; Reus et al. 2015; 
Bhattacharya et al. 2016). To address these questions, longitudinal studies are needed 
that investigate the relationship between markers of neuroinflammation and clinical 
outcomes.  
 
The aim of this study was to investigate if CSF markers of neuroinflammation and 
neuronal injury in patients with bipolar disorder predict important clinical outcomes 
during a 6-7 year follow up period. 
 
2. Methods 
2.1. Study population 
The study included 77 patients with bipolar disorder. The work-up procedures for 
patients at baseline have been described in detail previously (Ryden et al. 2009). 
Patients were recruited from the St. Göran Bipolar Project, enrolling patients from the 
Northern Stockholm psychiatric clinic, Stockholm, Sweden, between October 2005 
and April 2008. Inclusion criteria were an age of at least 18 years old and meeting the 
DSM-IV-TR criteria for any bipolar disorder spectrum diagnosis (bipolar disorder 
type 1, type 2, or not otherwise specified). The Affective Disorder Evaluation (ADE) 
was used to establish the diagnosis. The ADE is a semi-structured interview that 
includes adapted versions of the mood and psychosis modules of the Structured 
Clinical Interview for DSM-IV, and was developed for the Systematic Treatment 
Enhancement Program of Bipolar Disorder (STEP-BD) project (Sachs et al. 2003). 
Co-morbid psychiatric disorders were screened for by utilizing the Mini International 
Neuropsychiatric Interview (M.I.N.I.) (Sheehan et al. 1998). The ADE and M.I.N.I. 
interviews were conducted by board certified psychiatrists or residents in psychiatry. 
A best-estimate diagnostic decision (Leckman et al. 1982; Roy et al. 1997) was made 
by a consensus panel of experienced board-certified psychiatrists specialized in 
bipolar disorder treatment with access to patients records, ADE, M.I.N.I. and 
interviews with next of kin when possible. The Montgomery-Åsberg Depression 
Rating Scale (MADRS) and the Young Mania Rating Scale (YMRS) were used to 
assess depressive and manic symptoms in patients. Function and symptom severity 
were measured using the Clinical Global Impression (CGI) rating scale, and the 
Global Assessment of Functioning (GAF) Scale divided into function (GAF-f) and 
symptom (GAF-s).  
 
After approximately 6-7 years, patients were contacted and re-scheduled for all 
follow-up visits. Patients who had undergone a lumbar puncture at baseline, and who 
had completed the follow-up visit were eligible for this study. At the follow-up visit, 
all patients were interviewed by board certified psychiatrist (C.S. & C-J. E) using a 
structured interview that included a detailed review of mood episodes and events 
(suicide attempts, inpatient care) that had occurred during the follow-up period. The 
interviewers had access to patients’ electronic medical journals. The change in GAF 
score during the follow-up time (∆GAF) was calculated by subtracting GAF scores at 
baseline from GAF scores at follow-up.  
 
The study was approved by the Regional Ethics Committee in Stockholm and carried 
out in accordance with the Declaration of Helsinki. All participants gave oral and 
written consent to participate in the study.  
 
2.2. Lumbar puncture 
At baseline, CSF was obtained by lumbar puncture that occurred between 0900 and 
1000 hours following an overnight fast. Patients were in a stable euthymic mood as 
judged by a physician at the time of CSF sampling. A total volume of 12 ml was 
collected, inverted to avoid gradient effects, divided into aliquots and stored at -80ºC 
pending analyses. All samples in this study were thawed and refrozen once before 
analysis. 
 
2.3. CSF analyses 
IL-8 was analyzed together with IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, TNF-α, 
and IFN-γ using the MSD 96-well multi-array and multi-spot human cytokine assay 
(Human Cytokine Assay Ultra-Sensitive kit, Meso Scale Discovery). MCP-1 
concentration was measured using a commercial electrochemiluminescence enzyme-
linked immunosorbant assay (ELISA; Human MCP-1 Ultra-Sensitive Kit, Meso Scale 
Discovery). YKL-40 concentration was measured using a commercial colorimetric 
ELISA (Human chitinase-3 quantikine ELISA kit, R&D systems Inc.). NF-L 
concentration was measured with a commercial ELISA assay (NFLight, 
UmanDiagnostis AB, Umeå, Sweden).  
 
All analyses were performed according to the manufacturers' instructions at the 
Clinical Neurochemistry Laboratory in Mölndal, Sweden. Intra-assay coefficients of 
variation were below 10% for all assays. The staff performing the analyses was 
blinded to all phenotype information. 
 
2.4. Analysis of CSF/serum albumin ratio 
Serum and CSF concentrations of albumin were analyzed by immunonephelometry 
on a Beckman Immage Immunochemistry system (Beckman Instruments, Beckman 
Coulter, Brea, CA, USA), using a method accredited by the Swedish Board for 
Accreditation and Conformity Assessment (SWEDAC). Intra- and inter-assay 
coefficients of variation were below 10%. The ratio between the albumin 
concentration in CSF (mg/L) and serum (g/L) was calculated and used to assess 
blood-CSF barrier function (Andersson et al. 1994). 
 
2.5. Statistical analyses  
2.5.1. Rationale for selecting covariates to main regression analyses  
In order to select potentially confounding variables to adjust for in the main 
regression analyses (investigating associations between CSF analytes at baseline and 
clinical outcomes at 6-7 year follow-up), we first performed bivariate regression 
analyses testing possible associations between CSF analytes at baseline and clinical 
parameters at baseline. These parameters were age, sex, BMI (body mass index), 
CSF/serum albumin ratio, and pharmacological treatments (lithium, antipsychotic 
drugs, anticonvulsant drugs, antidepressant drugs, and benzodiazepines). Variables 
with a univariate correlation with a p-value <0.25 were included in ensuing multiple 
regression analyses (one for every CSF analyte). In a second step, we performed 
bivariate regression analyses testing possible associations between the main clinical 
outcomes and important clinical parameters at baseline. These were age, sex, BMI, 
CSF/serum albumin ratio, and pharmacological treatments (lithium, antipsychotic 
drugs, anticonvulsant drugs, antidepressant drugs, and benzodiazepines). Variables 
with a univariate correlation with a p-value <0.25 were included in ensuing multiple 
regression analyses (one for every clinical outcome). Variables with a p-value <0.05 
in the multiple regression analyses (either associated with the CSF analyte, with the 
clinical outcome or with both) were finally added as covariates in the main regression 
analyses. Dependent variables not showing a normal distribution (as tested by one-
sample Kolmogorov-Smirnov test) were log10 transformed prior to linear regressions 
to make the residuals more close to normal distribution.  
 
2.5.2. Main regression analyses 
For every CSF analyte (IL-8, MCP-1, YKL-40, NFL), five logistic regression 
analyses were performed, testing the associations between the analyte and the clinical 
outcomes manic/hypomanic episodes, depressive episodes, suicide attempts, inpatient 
care, and psychotic symptoms during mood episodes. To make the odds ratios more 
interpretable, the analytes were divided by their standard deviations prior to the 
logistic regressions. While evaluating goodness-of-fit for the regression analysis by 
the Hosmer-Lemeshow test, the models fitted the data best when using log10 
transformed values; therefore CSF analytes were log 10 transformed prior to 
regression analyses. Further, two linear regression analyses were performed for every 
CSF analyte, testing the associations between the analytes and the change in GAF-
symptom and GAF-function during the follow-up time. Variables identified by the 
selective procedure described above were used as covariates in all regression analyses 
to adjust for potential confounders. Level of significance was set at p<0.05. SPSS 
Statistics version 22 (IBM Corporation) was used for all statistical analyses. Because 
of the multiple statistical tests performed in this study, correction for the false 
discovery rate (FDR) was applied, using the Benjamini-Hochberg procedure 
(Benjamini and Hochberg 1995). To this end, an online utility was used (SDM-
ProjectWeb 2010).  
 
2.6. Description of lost to follow-up  
The clinical features of the population available for this follow-up study were 
compared with the study populations previously used for studying patient-control 
differences in CSF-markers at baseline (Jakobsson et al. 2014; Isgren et al. 2015; 




Demographic and clinical characteristics of the study population are presented in table 
1. The clinical data from the follow-up refers to clinical events that had occurred 
between baseline and the 6-7 year follow-up. At baseline, all patients undergoing 
lumbar puncture were euthymic as judged by a physician. The results from the 
MADRS and YMRS assessments at the time of lumbar puncture showed that 80% of 
the patients had MADRS scores below 12 and 100% of the patients had YMRS scores 
below 12.  
 
We compared individuals eligible for this study with the populations used for 
analyzing patient-control differences in CSF analytes at baseline (Jakobsson et al. 
2014; Isgren et al. 2015; Jakobsson et al. 2015). This comparison showed that patients 
in this study had had a longer disease duration at baseline (median 17 years vs. 12 
years). The other clinical features were similar. Supplementary table S1 shows a 
comparison between the follow-up study cohort and the cohort from the study of 
markers of monocyte and microglia activation (Jakobsson et al. 2015). The 
characteristics of the other two study baseline cohorts (Jakobsson et al. 2014; Isgren 
et al. 2015) were very similar to the Jakobsson (2015) study (data not shown). 
 
3.2. Associations between CSF analytes and clinical parameters at baseline 
At baseline, IL-8 was significantly associated with age (p=0.002; β=0.302), 
CSF/serum albumin ratio (p=0.006; β=0.295), and lithium treatment (p=0.006; 
β=0.294). MCP-1 was significantly associated with age (p=0.002; β=0.348). YKL-40 
was significantly associated with age (p=0.000; β=0.722), CSF/serum albumin ratio 
(p=0.027; β=0.168) and lithium treatment (p=0.013; β=0.184). NF-L was significantly 
associated with age (p=0.001; β=0.696) and CSF/serum albumin ratio (p=0.008; 
β=0.221). The multiple regression analyses are shown in detail in supplementary table 
S2.  
 
3.3. Associations between baseline variables and clinical outcomes at follow-up 
Manic/hypomanic episodes during the follow-up period was negatively associated 
with age (p=0.003; OR=0.928). Depressive episodes during the follow-up period was 
positively associated with antipsychotic (p=0.038; OR=10.3) and antidepressant 
(p=0.008; OR=5.46) treatments. Inpatient care was positively associated with the use 
of benzodiazepines (p=0.014; OR=6.06). Psychotic symptoms during mood episodes 
was negatively associated with age (p=0.014; OR=0.923) and positively associated 
with lithium treatment (p=0.014; OR=14.6). Suicide attempts or change in GAF 
scores during the follow-up time were not significantly associated with any of the 
clinical parameters.  
 
3.4. Associations between baseline markers of neuroinflammation and brain injury 
and clinical outcomes at follow-up 
There were no significant associations between IL-8 or NF-L and clinical outcomes 
after adding covariates to the analyses. MCP-1 concentrations were positively 
associated with having manic/hypomanic episodes and with inpatient care during the 
follow-up period. YKL-40 concentrations were negatively associated with having 
manic episodes and with having psychotic symptoms during mood episodes. When 
adjusting the p-values using an FDR-method, one significant finding remained: the 
negative association between YKL-40 and relapse into mania/hypomania. See table 2 
for a summary of the regression analyses and supplementary tables 3-6 for statistical 
details. 
 4. Discussion 
This is the first prospective study investigating if CSF markers of neuroinflammation 
and brain injury predict clinical outcomes in a long-term follow-up. We found that 
higher concentrations of YKL-40 were associated with lower risk of relapse into 
mania/hypomania. This finding was significant after correcting for multiple 
comparisons. We also found that higher concentrations of YKL-40 were associated 
with not having psychotic symptoms during mood episodes, and that higher 
concentrations of MCP-1 were associated with higher risk for manic/hypomanic 
episodes and inpatient care during the follow-up period. However, these three 
associations were not significant after adjusting the p-values for multiple testing. 
When inspecting the other statistically non-significant associations, of which some 
theoretically could be affected by low statistical power, neither of these suggest that 
high markers of neuroinflammation and neuronal injury would be associated with a 
poor prognosis. We therefore conclude that high levels of the CSF markers of 
neuroinflammation and neuronal injury - which we previously have shown to be 
elevated in patients with bipolar disorder - are not consistently associated with poor 
clinical outcomes. 
 
Our findings should be viewed in the context that it is as yet undecided if 
neuroinflammation and microglial activation reflect a pathological mechanisms in 
bipolar disorder, a reparative response to pathological mechanisms, or a general state 
of vulnerability for mood disorders (Mesman et al. 2015; Bhattacharya et al. 2016). 
Our results speak against an important role for these proteins in the progression of 
bipolar disorder, at least in a dose-dependent matter. The findings are partly in line 
with a prospective Dutch study that found higher serum levels of MCP-1 in bipolar 
offspring than in controls, together with higher expression of immune genes in 
monocytes (including MCP-1 gene). These aberrations were present irrespective of 
lifetime or future mood disorders. The authors suggested that the aberrant 
neuroimmune state in bipolar offspring reflects a general state of vulnerability for 
mood disorders rather than being of direct predictive value for development of a 
mood disorder (Mesman et al. 2015). 
 
There are no previous prospective study of CSF-biomarkers and course of illness in 
bipolar disorder, but a few studies have prospectively investigated the relationship 
between serum markers of neuroinflammation or peripheral inflammation and clinical 
outcomes in bipolar disorder. One study found that CRP (C-reactive protein) levels 
were significantly increased in depressed men who developed manic symptoms 
during two years of follow-up (Becking et al. 2013). Another study found that MCP-1 
and the pro-inflammatory cytokine IL-1α measured in serum predicted depressive 
relapse during a 12-month period after measurement (Bond et al. 2016). By contrast, 
we found no association between depressive relapses during the follow-up period and 
MCP-1 concentration in CSF.  
 
Previous cross-sectional studies have found lower CSF levels of IL-8 in suicide 
attempters with anxiety than in healthy controls (Janelidze et al. 2015), and lower 
CSF MCP-1 in suicide attempters than in healthy controls (Janelidze et al. 2013). In 
our prospective study, we found no significant associations between these analytes 
and suicide attempts during the follow-up period. This could, however, be due to the 
fact that only a few patients in this study attempted suicide during the follow-up 
period. 
 
It should be noted that the baseline CSF samples in this study were collected from 
euthymic bipolar disorder patients. It is possible that the results would have been 
different if CSF from patients with mania or depression would have been studied, 
since neuroimmune activation might be more prominent during mood episodes. For 
instance, a Danish meta-analysis of cytokines, cytokine receptors, and receptor 
antagonists found more prominent differences between patients with bipolar disorder 
and control subjects during mania and depression compared to during euthymia 
(Munkholm et al. 2013).  
 
Our study has limitations that should be considered. First, although we investigated 
the effects of many known potential confounders, there might be other factors that 
could not be controlled for in this study, e.g., physical activity and unrecorded 
medical conditions associated with inflammation. Second, although our study is the 
largest cohort of bipolar patients that has been followed-up after CSF collection, the 
sample size is yet limited which leads to power issues, especially when analyzing rare 
outcomes like suicide attempts. Third, the markers examined are proxies for, not 
direct measures of, neuroinflammation, microglial activation, and neuronal injury. 
Fourth, there is a risk of selection bias since some patients from baseline were lost to 
follow-up. However, the clinical characteristics of the study cohort were similar to 
those of the baseline cohorts. Finally, a limitation concerns correcting for the multiple 
tests performed in this study. Interpreting unadjusted p-values may lead to type I 
errors. But applying corrections for multiple testing as we did, might instead lead to 
type II errors.   
 
The strengths of this study include that protein concentrations were measured in CSF 
instead of in blood in contrast to the majority of previous studies in this area. This 
reduces the risks of measuring processes unrelated to the CNS. Another strength is 
that the cohort is well characterized with data on several important confounding 
factors, including the CSF/serum albumin ratio, and psychotropic drugs. The 
diagnostic procedures, including decisions by experienced board-certified 
psychiatrists specialized in bipolar disorder, ensures good diagnostic accuracy. 
 
In conclusion, our study shows that high levels of CSF markers of neuroinflammation 
and neuronal injury are not consistently associated with poor clinical outcomes in a 
long-term follow-up of bipolar disorder patients. Tentatively, the assessed proteins 
may be involved in adaptive immune processes or reflect a general state of 
vulnerability for mood disorders rather than being of predictive value for disease 
progression. Since bipolar disorder most certainly involve complex neuroimmune 
related mechanisms, along with complex nonimmune mechanisms, longitudinal 
studies across different mood states are needed to obtain a more complete picture of 
the neuroimmune mechanisms of bipolar disorder. 
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Table 1. Clinical characteristics of the study population.  
 Patients with bipolar disorder (N=77) 
Number (%) or median [IQR] 
Baseline data  
   Sex (m/f) 33 (57.1%) / 44 (42.9%) 
   Age (years) 37.0 [29.5-52.5] 
   BMI (kg/m2)a 25.6 [22.7-28.3] 
   Bipolar diagnosis a  
      I 38 (49.4%) 
      II 28 (36.4%) 
      Other 11 (14.3%) 
   Illness duration (years)a 17.0 [11.0-29.3] 
   Rating scales    
      CGIb 4.0 [4.0-5.0] 
      MADRSc 3.0 [1.0-10.5] 
      YMRSd 0.0 [0.0-2.0] 
      GAF-symptoma 68 [60-80] 
      GAF-functiona 68 [60-80] 
   Comorbid diagnoses (M.I.N.I.)  
      Anxiety disordersb 18 (23.3%) 
      Alcohol dependence or abusef 9 (12.5%) 
      Drug dependence or abusef 3 (4.2%) 
   Medications  
      Lithium 50 (64.9%) 
      Antipsychotics 16 (20.8%) 
      Anticonvulsants  24 (31.2%) 
      Antidepressants 34 (44.2%) 
      Benzodiazepines 19 (24.2%) 
   CSF proteins (pg/mL)  
      IL-8  34.0 [26.8-45.8] 
      MCP-1e 504 [415-635] 
      YKL-40 e 85.8 [52.8-122] 
      NFL 395 [232-607] 
6-7 year follow up data  
   Time between baseline LP and 
follow-up (years) 
6.4 [5.9-7.3] 
   Any manic/hypomanic episode a 34 (44.2%) 
   Any depressive episode e 53 (68.8%) 
   Any suicide attempt  7 (9.1%) 
   Any inpatient care 34 (44.2%) 
   Any psychotic symptoms e* 16 (20.8%) 
a Data missing for three patients b Data missing for four patients c Data missing for 14 
patients d Data missing for 17 patients eData missing for one patient f Data missing for 
5 patients * Psychotic symptoms during mood episodes 
Abbreviations: IQR, interquartile range. BMI, body mass index. CGI, clinical global 
impression. LP, lumbar puncture. MADRS, Montgomery-Åsberg depression rating 
scale. M.I.N.I., Mini international neuropsychiatric interview. YMRS, young mania 
rating scale. GAF, global assessment of functioning. 
 
  
Table 2. Results from regression analyses of concentrations of IL-8, YKL-40, MCP-
1, NF-L at baseline and clinical parameters at 6-7-year follow-up in patients with 
bipolar disorder.  
Clinical parameters IL-8 MCP-1 YKL-40 NFL 
























































Values in bold were significant at the 0.05 level (uncorrected p-values). Green color 
represents a positive association and red color represents a negative association. 
Abbreviations: β, standardized beta coefficients (linear regressions). GAF, global 
assessment of functioning. OR, odds ratio (logistic regressions). 
Covariates and statistical details in supplementary tables S3-6. 
